Subclinical hypothyroidism (SCH) and overt hypothyroidism (HT) are common diseases, affecting, respectively, 9.0% and 0.4% of the United States population \[[@B1]\], predominantly women. As thyroid function has multisystemic effects, its derangement could affect a broad range of cardiometabolic pathways potentially related to clinical manifestations. However, the definition of normal thyroid function has been intensely debated, with some experts advocating for lowering the upper limit of normal for thyroid stimulating hormone (TSH) \[[@B2]\] and others for maintaining the current standard \[[@B3]\]. In this regard, thyroid-related risk for incident type 2 diabetes (T2D) and cardiovascular disease (CVD) may impact the definition of TSH normality. In the one hand, HT has been associated with incident T2D \[[@B4]\]; on the other hand, findings are mixed for CVD, especially in the gray zone of SCH \[[@B5]\].

The potential relationship of thyroid hypofunction with T2D and CVD may be mediated by abnormalities in lipids, lipoprotein subclasses, endothelial function, coagulation, inflammatory pathways, and insulin resistance \[[@B9]\]. To date, there have been inconsistent data regarding thyroid function across the spectrum of euthyroid to HT and its potential cardiometabolic mediators, both in direction and magnitude \[[@B11]\]. Detailed assessment of thyroid function effects on these mediators/markers may have high population health implications, especially along the milder hypofunction spectrum within euthyroidism and SCH. Understanding the role of thyroid function in cardiometabolic pathways may guide the clinically relevant definition of thyroid function and unveil potential targets for controlling related morbidity.

Therefore, in this study of apparently healthy middle-aged and older women, we examined thyroid function across the spectrum of euthyroid to HT in relationship to cardiometabolic pathways represented by lipids, lipoproteins, inflammation, coagulation, glycemic, and insulin resistance biomarkers.

1. Methods {#s10}
==========

A. Study Design, Sample, and Exposure Assessment {#s11}
------------------------------------------------

The sample comprised apparently healthy middle-aged and older women at study entry of an ongoing prospective cohort, the Women's Health Study \[[@B14]\]. At enrollment, women gave written informed consent and completed questionnaires on demographics, anthropometrics, medical history, and lifestyle factors. Race was self-referred, and body mass index (BMI) was measured as weight in kilograms by squared height in meters. The study was approved by the Institutional Review Board of the Brigham and Women's Hospital (Boston, MA).

As our initial inclusion criteria were similar to the original protocol, that is, women without CVD or cancer, 28,024 participants with available stored frozen plasma at baseline were eligible for our study. From those, 3914 women were randomly selected for thyroid function testing, and after excluding those on lipid-lowering therapy and ineligible thyroid categories amounted to 3321 individuals. Eligible categories based on the Roche Cobas assay recommendations by Atherotech Diagnostics Laboratory (Birmingham, AL) were defined as follows: euthyroid \[TSH, 0.27 to 4.2 mIU/L; free thyroxine (FT4), 0.93 to 1.7 ng/dL), SCH (TSH \> 4.2 mIU/L; FT4, 0.93 to 1.7 ng/dL), and hypothyroid (TSH \> 4.2 mIU/L; FT4 \< 0.93 ng/dL). Thyroid category distributions were: euthyrodism, 2571 (77.4%); SCH, 573 (17.3%); and HT, 177 (5.3%). We performed additional analyses of TSH quintiles within normal FT4 individuals (0.93 to 1.7 ng/dL), which includes only euthyroid and SCH, 3144 (94.7%).

B. Biomarker Assessment {#s12}
-----------------------

Samples were obtained from stored blood in vapor-phase liquid nitrogen (−170°C) at the time of enrollment into the Women's Health Study and thawed for the following laboratory analyses. TSH and FT4 were measured at Atherotech Diagnostics Laboratory using the Roche Cobas e601 analyzer with coefficients of variation (CVs) of ≤8.7% and ≤6.6%, respectively. In a laboratory certified by the National Heart, Lung, and Blood Institute/Centers for Disease Control and Prevention Lipid Standardization program, standard lipids were measured directly with reagents from Roche Diagnostics (Indianapolis, IN) \[[@B15]\] and apolipoprotein (apo) B and A1 were measured with immunoturbidimetric assays (DiaSorin, Stillwater, MN). All measures had CVs of ≤5% and comprised total cholesterol, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, triglycerides, apoB, and apoA1. Lipoprotein(a) \[Lp(a)\] was measured with a well characterized in-house immunoturbidimetric assay using a Technicon Axon autoanalyser (Miles Inc., Tarrytown, NY), rabbit anti-human lipoprotein(a) polyclonal antibodies (Q023, DAKO, Glostrup, Denmark), and a human serum lipoprotein(a) calibrator (DAKO)\[[@B16]\]. Nuclear magnetic resonance (NMR) spectroscopy (LabCorp, previously LipoScience, Raleigh, NC) measured the methyl terminal of lipoprotein subclasses and size of LDL, HDL, and very-low-density lipoprotein (VLDL) particles using a targeted metabolomics platform (NMR LipoProfile analysis by the LP3 algorithm) \[[@B17]\]. This platform comprises concentrations of large, medium, and small VLDL particles; large and small LDL particles; very large, large, medium, small, and very small HDL particles; and average size of VLDL, LDL, and HDL particles. As the distribution of small LDL particles is bimodal in this population, we analyzed this parameter separately in those with concentrations higher or lower than 164 nmol/L, which is the nadir between modes. The group with the higher small LDL concentration is referred to as pattern B; the group with the lower small LDL concentration is referred to as pattern A. The lipoprotein insulin resistance (LPIR) score is part of the same panel, and is a weighted composite score of lipoprotein subclasses independently related to insulin resistance \[[@B18]\]. It includes 6 parameters (respective maximum points and direction for more insulin resistance): VLDL size (32 points, larger size); large VLDL particles (22 points, increasing concentration); LDL size (6 points, smaller size); small LDL particles (8 points, increasing concentration); HDL size (20 points, smaller size); and large HDL particles (12 points, decreasing concentration). The summed score ranges from 0 to 100, and higher values indicate increasing insulin resistance \[[@B18]\].

The inflammation and coagulation biomarkers were: high-sensitivity C-reactive protein (hs-CRP) measured by a high-sensitivity immunoturbidimetric assay on a Hitachi 917 autoanalyzer (Roche Diagnostics), with reagents and calibrators from Denka Seiken \[[@B19]\]; fibrinogen measured by an immunoturbidimetric assay (Kamiya Biomedical, Seattle, WA); homocysteine measured by an enzymatic assay (Catch Inc., Seattle, WA); and soluble intercellular adhesion molecule 1 (sICAM-1) measured by an enzyme-linked immunosorbent assay (R&D Systems, Minneapolis, MN). Additionally, glycan *N*-acetylglucosamines (GlycA) is a novel composite inflammatory biomarker of acute phase glycoproteins, mostly *α*1-acid glycoprotein, haptoglobin, *α*1-antitrypsin, *α*1-antichymotrypsin, and transferrin \[[@B20]\]. Their *N*-acetyl methyl group protons of the *N*-acetylglucosamine moieties located on their biantennary, triantennary, and tetraantennary branches were measured by magnetic resonance. This signal only arises from the *N*-acetylglucosamine units with *β*1→2 and *β*1→6 linkages on preceding mannose residue centered at 2.00 ± 0.01 ppm. GlycA signal was successfully deconvoluted from neighboring lipoprotein, majorly triglyceride concentration in VLDL, with a CV of 4.3% \[[@B20]\]. Hemoglobin A1c (HbA1c) was measured by turbidimetric immunoinhibition on hemolyzed whole blood or packed red cells (Roche Diagnostics). Metabolic syndrome was classified by the presence of at least of 3 of the following: HbA1c ≥5.7 or diabetes history; blood pressure ≥130/85, hypertension diagnosis or treatment; BMI \>26.7 kg/m^2^; triglycerides ≥150 mg/dL; or HDL cholesterol \<50 mg/dL. As waist circumference was not measured until year 6 of follow-up, baseline BMI was used instead. BMI baseline cut point was chosen according to the same percentile for BMI at year 6 as for 88-cm waist circumference at that moment.

C. Statistical Analysis {#s13}
-----------------------

Descriptive demographics of functional thyroid categories were displayed by percentages for categorical variables, and by mean (standard deviation) continuous variables. For univariable statistical comparisons, we used Cochran-Mantel-Haenszel for categorical variables and linear regression for trend for continuous variables.

We addressed the relationship of thyroid categories with each biomarker by adjusted linear regression analysis, with tests for linear trend, and pairwise comparisons adjusted by Bonferroni in the thyroid categories and TSH quintiles. For TSH quintiles, we tested linear trend across median TSH values within each quintile. For pairwise comparisons, the respective references were euthyroid or the bottom TSH quintiles. The covariables were age, race, household income, current smoking, systolic blood pressure, antihypertensive treatment, menopause status, and hormone replacement therapy. Skewed distributed variables were transformed by the natural logarithm \[HDL cholesterol, triglycerides, Lp(a), large and small VLDL particles, small LDL particles (pattern B), hs-CRP, fibrinogen, homocysteine, and HbA1c\] or by the square root (very large, large, medium, and small HDL particles) for better model fit, and then back transformed. We also conducted sensitivity analyses adjusted for BMI to address possible mediation of adiposity on thyroid function and metabolic abnormalities.

Finally, to assess the risk of having clinical metabolic syndrome across the thyroid categories or TSH quintiles, we applied logistic regression adjusted for age, race, smoking status, income, menopause status, and hormone replacement therapy. Analyses were performed using SAS version 9.3 (SAS Institute, Cary, NC).

2. Results {#s14}
==========

Compared with euthyroid women, those with SCH and HT were older and had higher BMI, greater prevalence of postmenopausal status, lower prevalence of current smoking, higher blood pressure, and greater prevalence of metabolic syndrome ([Table 1](#T1){ref-type="table"}). Noticeably, metabolic syndrome prevalence (25.4% on euthyroid to 39.6% on HT) and smoking (18.2% on euthyroid to 11.3% on HT) were largely different across thyroid categories.

###### 

**Baseline Clinical Characteristics by Thyroid Function**

  Variable                                     Euthyroid (77.4%; N = 2571)   SCH  (17.3%; N = 573)   HT  (5.3%; N = 177)   *P* Value for Trend
  -------------------------------------------- ----------------------------- ----------------------- --------------------- ---------------------
  Age, y                                       56.5 (7.8)                    58.5 (8.3)              60.4 (8.6)            \<0.001
  White, N (%)                                 2451 (96.2)                   558 (98.4)              174 (99.4)            \<0.001
  BMI, kg/m^2^                                 25.8 (5.0)                    26.1 (4.9)              26.8 (4.9)            0.005
  Income, annual household \> 50K USD, N (%)   1208 (50.0)                   235 (43.0)              66 (38.6)             \<0.001
  Postmenopausal, N (%)                        1575 (61.4)                   402 (70.2)              134 (75.7)            \<0.001
  Hormone replacement treatment, N (%)         1092 (42.5)                   260 (45.6)              66 (37.3)             0.843
  Diabetes, N (%)                              95 (3.7)                      27 (4.7)                10 (5.7)              0.105
  HbA1c, %                                     5.0 (4.8--5.2)                5.0 (4.8--5.2)          5.1 (4.9--5.3)        \<0.001
  Family history of diabetes, N (%)            672 (26.1)                    154 (26.9)              45 (25.4)             0.950
  Current smoking, N (%)                       496 (18.2)                    55 (9.6)                20 (11.3)             \<0.001
  Systolic blood pressure, mm Hg               125 (14)                      126 (14)                128 (14)              \<0.001
  Diastolic blood pressure, mm Hg              77 (9)                        77 (9)                  79 (9)                0.017
  Hypertension history, N (%)                  694 (27.0)                    167 (29.1)              56 (31.6)             0.108
  Metabolic syndrome, N (%)                    650 (25.4)                    175 (30.7)              70 (39.6)             \<0.001

Values are shown as mean (standard deviation) or number (percentage). For *P* values, the Cochran--Mantel--Haenszel test for categorical variables and linear regression for linear trend for continuous variables were used.

In analyses that adjusted for age, race, household income, current smoking, systolic blood pressure, antihypertensive treatment, menopause status, and hormone replacement therapy, across thyroid categories there were no significant contrasts for total cholesterol, LDL cholesterol, ApoA1, or Lp(a) ([Table 2](#T2){ref-type="table"}). By contrast, going from euthyroid to SCH and HT, there was a pattern of increasing atherogenic dyslipidemia, namely, lower HDL cholesterol, higher triglycerides, higher ApoB concentrations, as well as higher triglyceride/HDL-c ratios and apoB/Apoa1 ratios. Additional adjustment for BMI did not change the results.

###### 

**Adjusted Standard Lipids and Apolipoprotein According to Functional Thyroid Categories**

  Variable                   Euthyroidism        SCH                                                    HT                                                     P for Linear Trend
  -------------------------- ------------------- ------------------------------------------------------ ------------------------------------------------------ --------------------
  Total cholesterol, mg/dL   213 (212, 215)      212 (208, 215)                                         218 (212, 224)                                         0.621
  LDL cholesterol, mg/dL     126 (124, 127)      124 (121, 127)                                         128 (123, 133)                                         0.976
  HDL cholesterol, mg/dL     51.6 (51.1, 52.2)   49.3 (48.2, 50.4)[*^a^*](#t2n1){ref-type="table-fn"}   49.4 (47.4, 51.4)                                      \<0.001
  Triglycerides, mg/dL       122 (120, 125)      133 (128, 139)[*^a^*](#t2n1){ref-type="table-fn"}      141 (131, 153)[*^a^*](#t2n1){ref-type="table-fn"}      \<0.0001
  Triglycerides/HDL ratio    2.4 (2.3, 2.4)      2.7 (2.5, 2.9)[*^a^*](#t2n1){ref-type="table-fn"}      2.9 (2.6, 3.2)[*^a^*](#t2n1){ref-type="table-fn"}      \<0.0001
  ApoB, mg/dL                105 (104, 106)      106 (104, 109)                                         112 (107, 116)[*^a^*](#t2n1){ref-type="table-fn"}      0.011
  ApoA1, mg/dL               150 (149, 151)      148 (146, 150)                                         147 (143, 151)                                         0.074
  ApoB/ApoA1 ratio           0.73 (0.72, 0.74)   0.74 (0.72, 0.76)                                      0.80 (0.76, 0.84)[*^a^*](#t2n1){ref-type="table-fn"}   0.001
  Lp(a), mg/dL               11.2 (10.6, 11.8)   10.9 (9.7, 12.2)                                       11.1 (9.1, 13.5)                                       0.788

For linear regression across categories, adjustment covariates included age, race, household income, current smoking, systolic blood pressure, antihypertensive treatment, menopause status, and hormone replacement therapy. Least square means (95% CI) were determined.

*P* \< 0.050 for pairwise comparison with euthyroid category (Bonferroni adjusted). Additional adjustment for BMI did not yield a change in *P* for trend across 0.05 thresholds.

On examining the lipoprotein particle distributions, there was a trend toward increasing insulin resistance going from euthyroid to SCH and HT ([Table 3](#T3){ref-type="table"}). In this order, there were increasing concentrations of large and medium VLDL particles, reflected by increasing VLDL size. Regarding LDL subclasses, from ET to HT there were increasing concentrations of total LDL particles and particularly of the small LDL (pattern B). This resulted in a smaller average LDL particle size. In contrast to differences seen in LDL particles, there were no HDL particle differences across thyroid categories. The LPIR score reflected the overall profile of the lipoprotein subclasses, as indicated by greater lipoprotein insulin resistance going from a euthyroid mean LPIR score of 49.2 (95% CI, 48.3, 50.2) to 52.1 in SCH (95% CI, 50.1, 54.0) and 52.1 in HT (95% CI, 48.6, 55.6)(*P* for trend of 0.008). Additional adjustment for BMI neutralized differences for LDL particle size and LPIR signaled ([Table 3](#T3){ref-type="table"}).

###### 

**Adjusted Analysis for Lipoprotein Particle Concentration and Size According to Functional Thyroid Categories**

  Variable                                                                         Euthyroidism        SCH                                                  HT                                                     *P* for Linear Trend
  -------------------------------------------------------------------------------- ------------------- ---------------------------------------------------- ------------------------------------------------------ ------------------------------------------
  VLDL particles                                                                                                                                                                                                   
   Total, nmol/L                                                                   61.8 (60.7, 62.8)   62.7 (60.6, 64.9)                                    65.2 (61.4, 69.1)                                      0.084
   Large, nmol/L                                                                   2.5 (2.4, 2.6)      2.7 (2.5, 3.0)                                       3.1 (2.7, 3.6)[*^a^*](#t3n1){ref-type="table-fn"}      0.002
   Medium, nmol/L                                                                  16.9 (16.4, 17.3)   17.8 (16.8, 18.7)                                    19 (17.4, 20.7)[*^a^*](#t3n1){ref-type="table-fn"}     0.005
   Small, nmol/L                                                                   36.1 (35.2, 36.9)   36.0 (34.3, 37.8)                                    35.6 (32.6, 38.7)                                      0.804
   Average size, nm                                                                51.5 (51.2, 51.8)   52.3 (51.7, 53)                                      52.9 (51.8, 54.1)[*^a^*](#t3n1){ref-type="table-fn"}   0.001
  IDL partcles                                                                                                                                                                                                     
   Total, nmol/L                                                                   179 (175, 183)      176 (167, 184)                                       188 (174, 203)                                         0.674
  LDL particles                                                                                                                                                                                                    
   Total, nmol/L                                                                   1283 (1267, 1299)   1319 (1285, 1353)                                    1358 (1298, 1418)                                      0.004
   Large, nmol/L                                                                   575 (564, 586)      552 (529, 576)                                       562 (520, 604)                                         0.157
   Small pattern B 2225 (67.0%)                                                    668 (653, 684)      734 (699, 770)[*^a^*](#t3n1){ref-type="table-fn"}    829 (759, 906)[*^a^*](#t3n1){ref-type="table-fn"}      \<0.001
   Small pattern A 1096 (33.0%)                                                    64.8 (63.0, 66.6)   63.8 (60.0, 67.8)                                    62.5 (56.5, 69.1)                                      0.456
   Average size, nm                                                                21.1 (21.0, 21.1)   21 (20.9, 21.1)                                      21 (20.9, 21.1)                                        0.024[*^b^*](#t3n2){ref-type="table-fn"}
  HDL particles                                                                                                                                                                                                    
   Total, nmol/L                                                                   37.4 (37.2, 37.7)   37.3 (36.8, 37.8)                                    37.1 (36.1, 38.0)                                      0.431
   Large, μmol/L                                                                   6.3 (6.2, 6.4)      6.1 (5.8, 6.3)                                       6.4 (5.9, 6.9)                                         0.433
   Medium, μmol/L                                                                  12.5 (12.3, 12.7)   12.6 (12.1, 13)                                      12.8 (12, 13.6)                                        0.602
   Small, μmol/L                                                                   18.7 (18.5, 18.9)   19.1 (18.6, 19.5)                                    18.1 (17.4, 18.9)                                      0.904
   Average size, nm                                                                9.2 (9.2, 9.2)      9.2 (9.1, 9.2)                                       9.3 (9.2, 9.3)                                         0.987
   Lipoprotein insulin resistance index score[*^b^*](#t3n2){ref-type="table-fn"}   49.2 (48.3, 50.2)   52.1 (50.1, 54)[*^a^*](#t3n1){ref-type="table-fn"}   52.1 (48.6, 55.6)                                      0.008[*^b^*](#t3n2){ref-type="table-fn"}

For linear regression across categories, adjustment covariates included age, race, household income, current smoking, systolic blood pressure, antihypertensive treatment, menopause status, and hormone replacement therapy. Least square means (95% CI) were determined. The small LDL pattern A group had 1096 individuals and the small LDL pattern B group had 2225 individuals, which corresponds to 33.0% and 67.0% of all those with available small LDL particles.

*P* \< 0.050 for pairwise comparison with euthyroid category (Bonferroni adjusted).

Additional adjustment for BMI yield change in *P* for trend across 0.05 threshold.

For inflammatory and coagulation biomarkers, there were mixed results across thyroid categories ([Table 4](#T4){ref-type="table"}). Mean hs-CRP levels increased from 2.0 mg/L (95% CI, 1.9, 2.1) in euthyroid to 2.1 mg/L (95% CI, 1.9, 2.3) in SCH and 2.4 mg/L (95% CI, 2.0, 2.8) in HT (*P* for trend of 0.028); however, it was null after BMI adjustment. In contrast, no significant differences were noted for the other inflammatory/coagulation biomarkers. HbA1c levels were all below the upper limit of normality across thyroid categories, although a small but statistically significant difference was noted comparing HT with euthyroid.

###### 

**Inflammatory, Coagulation, and Metabolism Markers by Thyroid Function Classification**

  Variable               Euthyroidism        SCH                 HT                                                  *P* for Linear Trend
  ---------------------- ------------------- ------------------- --------------------------------------------------- ------------------------------------------
  hs-CRP, mg/L           2.0 (1.9, 2.1)      2.1 (1.9, 2.3)      2.4 (2.0, 2.8)                                      0.028[*^a^*](#t4n1){ref-type="table-fn"}
  Fibrinogen, mg/dL      361 (358, 364)      362 (356, 369)      357 (345, 369)                                      0.865
  Homocysteine, µmol/L   10.8 (10.7, 10.9)   10.9 (10.6, 11.2)   10.8 (10.3, 11.4)                                   0.712
  sICAM-1, ng/ml         368 (365, 372)      368 (360, 375)      376 (363, 389)                                      0.446
  GlycA, μmol/L          381 (378, 384)      380 (375, 386)      381 (371, 391)                                      0.924
  HbA1c, %               5.1 (5.1, 5.1)      5.1 (5.1, 5.2)      5.2 (5.1, 5.3)[*^b^*](#t4n2){ref-type="table-fn"}   0.011

For linear regression across categories, adjustment covariates included age, race, household income, current smoking, systolic blood pressure, antihypertensive treatment, menopause status, and hormone replacement therapy. Least square means (95% CI) were determined.

Additional adjustment for BMI yield change in *P* for trend across 0.05 threshold.

*P* \< 0.050 for pairwise comparison with euthyroid category (Bonferroni adjusted).

On analysis restricted to euthyroid and SCH women (Supplemental Tables 1--3), TSH quintile values were mostly within the normal range (*i.e.,* euthyroid). Only the top TSH quintile had individuals in the SCH range, which comprised 91.0% (573 women) of the top quintile. Similar to the analyses for thyroid categories, across increasing TSH quintiles the overall profile was consistent with worsening dyslipidemia and dyslipoproteinemia. In contrast to the analysis according to thyroid categories, we noted that there were decreasing concentrations of large HDL particles and increasing concentrations of small HDL particles from the bottom to the top quintile, reflected in smaller HDL particles size. Of note, increasing TSH quintiles presented quite linear LPIR increments (Supplemental Table 2; [Fig. 1](#F1){ref-type="fig"}).

![LPIR according to TSH quintiles. LPIR score differences for TSH quintiles (Q) vs the first TSH quintile along euthyroid and SCH are shown. For linear regression for median TSH across categories, adjustment covariates include age, income, current smoking, race, household income, systolic blood pressure, high blood pressure treatment, menopause status, and hormone replacement therapy. The *P* value for the trend for median TSH values within each quintile is shown. \*Bonferroni adjusted *P* value = 0.010 for the fifth quintile vs the first quintile.](js-01-113-f1){#F1}

Regarding metabolic syndrome, there was increasing prevalence from ET to HT (*P* \< 0.001). Compared with euthyroid, SCH and HT adjusted odds ratios for metabolic syndrome were, respectively, 1.37 (95% CI, 1.08, 1.73) and 1.88 (95% CI, 1.30, 2.72) (*P* for linear trend of \<0.001). Increasing TSH within euthyroid and SCH range had higher odds ratios for metabolic syndrome in reference to the bottom quintile (*P* for trend of 0.001) (Supplemental Table 4), in which the top quintile had an odds of 1.49 (95% CI, 1.10, 2.01).

3. Discussion {#s15}
=============

In this population of apparently healthy middle-aged and older women, individuals with SCH and HT had differences in the lipid and lipoprotein subclass profile that indicated worsening insulin resistance and higher cardiometabolic risk compared with euthyroid individuals, despite having similar LDL cholesterol and total cholesterol. Of the other biomarkers, only hs-CRP and HbA1c were associated with SCH and HT. For TSH quintiles mostly within the normal range, lipid and lipoprotein results for TSH quintiles were generally similar but null for other biomarkers. Hence, progressive thyroid hypofunction was associated with insulin-resistant and proatherogenic lipids and lipoproteins profile in a graded manner, with potential clinical consequences.

This study adds to the literature by describing the graded relationship of progressive thyroid hypofunction, even within the "normal" range of euthyroidism, as manifested by increasing lipoprotein insulin resistance. For inflammatory, coagulation, and glucose metabolism biomarkers, only hs-CRP and HbA1c were higher across the euthyroid to HT spectrum, but none of those biomarkers was higher along the TSH spectrum within euthyroid and SCH. Given that, the current classification of euthyroidism, SCH, and HT may be less sensitive to earlier thyroid disturbances within euthyroidism, in particular in relationship to insulin resistance--related dyslipidemia/dyslipoproteinemia.

We studied an apparently healthy population of women who were predominantly insulin sensitive (89% with HbA1c \< 5.7%). Should the progressive insulin resistance--related dyslipidemia along thyroid hypofunction have any impact on clinical outcomes as incident T2D or CVD, even small relative risk may have a high population impact. This is due to the very broad generalizability of our findings, as euthyroid and SCT women comprise 97.3% of middle-aged women in the United States \[[@B1]\]. Previous studies have found strong associations for LPIR with incident T2D \[[@B21], [@B22]\], and also in the current Women's Health Study population \[[@B23]\]. The robust association between thyroid and LPIR may be a pathophysiological pathway of its hypofunction toward T2D. For CVD, despite neutral risk with increasing TSH levels within the euthyroid range \[[@B24]\], the role of SCH is still open to debate \[[@B25]\]. In these contexts, our findings suggest that lipids and lipoproteins are potentially important mediators for therapeutic targeting beyond TSH replacement.

The literature regarding euthyroid and hypothyroid relationships with the panel of biomarkers that we examined is rather mixed. For standard lipids, the association of thyroid hypofunction with low HDL cholesterol and high triglycerides has been shown in a population study with \>30,000 euthyroid people \[[@B12]\]. Alternatively, in the Framingham Offspring Study population, there was no association between TSH and either HDL cholesterol or triglycerides \[[@B11]\]. Additionally, in the 2 studies mentioned previously there was higher total and LDL cholesterol for increasing TSH. However, it is not possible to infer to which extent population profile and adjustment models explain the divergent results.

Regarding lipoprotein subclasses, Hernández-Mijares \[[@B26]\] found, similarly to the current study, an increasing proportion of LDL pattern B profile patients from euthyroid to SCH. However, they did not address LDL subclasses across the euthyroidism range. In contrast, Pearce *et al.* \[[@B11]\] found lipoprotein subclass profiles totally opposite to the present results, toward insulin sensitivity in analyses adjusted for age, BMI, systolic blood pressure, antihypertensive treatment, diabetes, smoking, HDL cholesterol, and triglycerides. Nevertheless, thyroid hypofunction seems to equally affect HDL cholesterol, triglyceride, and lipoprotein subclasses toward insulin resistance profile. After further adjusting our current models for HDL and triglycerides, lipoprotein subclass profiles on SCH and HT were null or compatible with insulin sensitiveness (data not shown), similar to the study by Pearce *et al.* \[[@B11]\]. Thus, the collinear effect of thyroid hypofunction on HDL, triglyceride, and lipoprotein subclasses could justify those paradoxical results.

Regarding inflammation, in our study SCH and HT were associated with high hs-CRP, but not after adjustment for BMI. Lee *et al.* \[[@B27]\] also found no association of thyroid function with hs-CRP adjusted for BMI, which raises the hypothesis of BMI mediation between thyroid and inflammation. Also, Hueston *et al.* \[[@B28]\] did not find association of SCH with hs-CRP or homocysteine levels in a US adult population (National Health and Nutrition Examination Survey). However, the authors did not adjust for smoking, which is positively associated with inflammation \[[@B29]\] and inversely with HT \[[@B30]\]. This is corroborated by the fact that in our study there was no hs-CRP difference for euthyroid, SCH, and HT when smoking was not adjusted for (data not shown). Regarding homocysteine, Zhou *et al.* \[[@B13]\] also did not find an association with SCH, but they did find a positive association with HT. Nevertheless, in that meta-analysis, there was evidence for study heterogeneity and publication bias. Fibrinogen, a marker of hypercoagulation state, was similarly not associated with HT in other studies \[[@B31], [@B32]\], despite their limited adjustment for confounders. sICAM-1, associated with initiation and formation of atherosclerosis in animal models \[[@B33]\], and GlycA, a novel composite marker of acute phase glycoproteins signaling chronic inflammation \[[@B20]\], were both not associated with thyroid hypofunction in the present study. To the best of our knowledge, the association of euthyroidism, SCH, and HT with sICAM-1 and GlycA has not been reported previously. Finally, reverse causation for thyroid function and inflammation should be considered. The most common cause for thyroid hypofunction is Hashimoto disease \[[@B34]\], which may confound the association by its inflammatory pathophysiology. We could not address this hypothesis due to unavailable thyroid peroxidase antibodies.

A. Underlying Mechanisms {#s16}
------------------------

Thyroid hormones act as modulators of cholesterol synthesis and degradation through key enzymes. One of the main mechanisms is the stimulus of thyroid hormones over sterol regulatory element--binding protein 2, which in turn induces LDL receptor gene expression \[[@B35]\]. However, it was shown that the association of HT and higher LDL cholesterol levels is present only in insulin-resistant subjects \[[@B36]\]. Indeed, the lack of LDL cholesterol differences could be explained by our insulin-sensitive study population (low HbA1c levels). HT has also been associated with lower catabolism of lipid-rich lipoproteins by lipoprotein lipase \[[@B37]\], hepatic lipase \[[@B38]\], and decreased activity of cholesterol ester transfer protein \[[@B39]\] that mediates exchanges of cholesteryl esters of HDL particles with triglyceride-rich LDL and VLDL particles. These mechanisms might explain the relationship of thyroid hypofunction with atherogenic and insulin-resistant lipid and lipoprotein abnormalities.

Finally, the milder differences noted in HbA1c compared with LPIR across thyroid categories may be explained by the earlier effects of insulin resistance on lipoprotein metabolism than on glucose metabolism \[[@B40]\].

B. Strengths and Limitations {#s17}
----------------------------

Our study has a relatively large sample of apparently healthy middle-aged and older women free of CVD, which may limit generalizability to men or higher risk woman. The study design is cross-sectional, which limits any causal inferences. Additionally, there is no information about duration of thyroid dysfunction as well as thyroid hormone replacement and/or thyroid-modulating drugs. In spite of that, these factors may have limited impact given that our sample is composed of apparently healthy women on enrollment. We had an unprecedented comprehensive set of biomarkers, which offered a broad perspective on pathways between thyroid hypofunction and cardiometabolic risk. Despite the large number of biomarkers examined, insulin resistance is the common biological mechanism that is likely underlying the overall findings. Therefore, it is improbable that our results were due to chance alone.

4. Conclusion {#s18}
=============

In this large population of apparently healthy women, individuals with SCH had differences in their biomarker profile that indicated worsening lipoprotein insulin resistance and higher cardiometabolic risk compared with euthyroid individuals, despite having similar LDL cholesterol and total cholesterol levels. These findings suggest that cardiometabolic risk may increase early in the progression toward SCH and overt HT.
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